Interpace Biosciences

Interpace Biosciences is a commercial-stage molecular diagnostics company with a mission to deliver evidence-based tests for the early diagnosis and risk assessment of cancer. Its primary achievement is the development and commercialization of a complementary genomic and microRNA testing platform for thyroid nodules, which has established clinical utility in guiding patient management. The company's strategy is to leverage its integrated bioinformatics and commercial capabilities to dominate its niche in thyroid diagnostics while exploring research collaborations for future test development. Following the 2022 sale of its pharma services division, Interpace is now a focused, independent diagnostics entity.

A synergistic diagnostic platform combining Next-Generation Sequencing (NGS) for DNA mutation profiling (ThyGeNEXT®) with a proprietary microRNA (miRNA) expression classifier (ThyraMIR®v2) to provide comprehensive genomic and transcriptomic risk stratification.

Competes directly with Veracyte's Afirma® GSC, Quest/Mayo's ThyroSeq®, and CBLPath's RosettaGX® Reveal in the thyroid molecular diagnostics market. Interpace's key differentiation is its commercialized two-test (DNA + miRNA) strategy, but it faces significant challenges in market penetration against larger, better-capitalized competitors.